Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis

EBİNÇ, Haksun; TULMAÇ, Murat; DOĞRU, MEHMET TOLGA; ŞİMŞEK, Vedat; özer, murat; Ceneli, Ozcan

Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis

Murat TULMAÇ, (Kırıkkale Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Kırıkkale, Türkiye)

Haksun EBİNÇ, (Kırıkkale Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Kırıkkale, Türkiye)

Mehmet Tolga DOĞRU, (Kırıkkale Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Kırıkkale, Türkiye)

Murat ÖZER, (Kırıkkale Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Kırıkkale, Türkiye)

Özcan ÇENELİ, (Kırıkkale Üniversitesi, Tıp Fakültesi, Hematoloji Anabilim Dalı, Kırıkkale, Türkiye)

Vedat ŞİMŞEK (Numune Hastanesi, Anesteziyoloji ve Reanimasyon Kliniği, İstanbul, Türkiye)

Yeni Tıp Dergisi

2 0

Yıl: 2008 Cilt: 25 Sayı: 3 Sayfa Aralığı: 189 - 191 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis

Öz:

Heparin induced thrombocytopenia (HIT) is an immune mediated event that may result in life and limb threatening complications. We report a 52 year old diabetic woman with subacute instent thrombosis and severe heparin induced thrombocytopenia treated successfully with fondaparinux. Not only platelet count returned to normal but also thromboembolic or hemorrhagic events were prevented under treatment. The low rate of de novo antibody formation and the scarce cross-reactivity with HIT antibodies offer fondaparinux as a relatively safe alternative anticoagulant agent for use in patients with HIT. Fondaparinux should be kept in mind in severe HIT if direct thrombin inhibitors are unavailable.

Anahtar Kelime: Female fondaparinux Middle Aged Thrombosis Thrombocytopenia Heparin

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Ahmed I, Majeed A and Powell R. Heparin induced thrombocytopenia: diagnosis and management update Postgrad. Med J 2007;83: 575–82.
2. Efird LE, Kockler DE. Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia. Ann Pharmacother 2006;40: 1383-7.
3. Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Ann Intern Med 974;80:477–81.
4. Keeling DM, Richards EM, Baglin TP. Platelet aggregation in response to four low molecular weight heparins and the heparinoid ORG 10172 in patients with heparin-induced thrombocytopenia. Br J Haematol 1994; 86: 425–6.
5. Package insert. Argatroban (argatroban). Research Triangle Park, NC: GlaxoSmithKline, April 2005.
6. Package insert. Refludan (lepirudin). Montville, NJ: Berlex, October 2004.
7. Package insert. Angiomax (bivalirudin). Parsippany, NJ: The Medicines Company, December 2005.
8. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest 2005;127: 1S-8S.
9. Mulot A, Moulin F, Fohlen-Walter A, Angioi M, Sghaier M, Carteaux JP, et al. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol 2004;77: 67-71.
10. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparininduced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4: 759–65.
11. Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993;84: 322–8.
12. Bussey H, Francis JL. Heparin Consensus Group. Heparin overview and issues. Pharmacotherapy 2004;24:103S-107S.
13. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007;356: 2653–5.
14. Warkentin T.E. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)- Bridging the River Coumarin editorial Thromb Haemost 2008;99: 2–3.
15. Pouplard C, Couvret C, Regina S, Gruel Y. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005;3: 2813–5.
16. Greinacher A, Gopinadhan M, Gunther JU, Omer-Adam MA, Strobel U, Warkentin TE, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006;26: 2386–93.
17. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin Blood 2005;105: 139-144.

APA	TULMAÇ M, EBİNÇ H, DOĞRU M, özer m, Ceneli O, ŞİMŞEK V (2008). Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. , 189 - 191.
Chicago	TULMAÇ Murat,EBİNÇ Haksun,DOĞRU MEHMET TOLGA,özer murat,Ceneli Ozcan,ŞİMŞEK Vedat Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. (2008): 189 - 191.
MLA	TULMAÇ Murat,EBİNÇ Haksun,DOĞRU MEHMET TOLGA,özer murat,Ceneli Ozcan,ŞİMŞEK Vedat Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. , 2008, ss.189 - 191.
AMA	TULMAÇ M,EBİNÇ H,DOĞRU M,özer m,Ceneli O,ŞİMŞEK V Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. . 2008; 189 - 191.
Vancouver	TULMAÇ M,EBİNÇ H,DOĞRU M,özer m,Ceneli O,ŞİMŞEK V Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. . 2008; 189 - 191.
IEEE	TULMAÇ M,EBİNÇ H,DOĞRU M,özer m,Ceneli O,ŞİMŞEK V "Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis." , ss.189 - 191, 2008.
ISNAD	TULMAÇ, Murat vd. "Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis". (2008), 189-191.

APA	TULMAÇ M, EBİNÇ H, DOĞRU M, özer m, Ceneli O, ŞİMŞEK V (2008). Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. Yeni Tıp Dergisi, 25(3), 189 - 191.
Chicago	TULMAÇ Murat,EBİNÇ Haksun,DOĞRU MEHMET TOLGA,özer murat,Ceneli Ozcan,ŞİMŞEK Vedat Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. Yeni Tıp Dergisi 25, no.3 (2008): 189 - 191.
MLA	TULMAÇ Murat,EBİNÇ Haksun,DOĞRU MEHMET TOLGA,özer murat,Ceneli Ozcan,ŞİMŞEK Vedat Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. Yeni Tıp Dergisi, vol.25, no.3, 2008, ss.189 - 191.
AMA	TULMAÇ M,EBİNÇ H,DOĞRU M,özer m,Ceneli O,ŞİMŞEK V Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. Yeni Tıp Dergisi. 2008; 25(3): 189 - 191.
Vancouver	TULMAÇ M,EBİNÇ H,DOĞRU M,özer m,Ceneli O,ŞİMŞEK V Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis. Yeni Tıp Dergisi. 2008; 25(3): 189 - 191.
IEEE	TULMAÇ M,EBİNÇ H,DOĞRU M,özer m,Ceneli O,ŞİMŞEK V "Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis." Yeni Tıp Dergisi, 25, ss.189 - 191, 2008.
ISNAD	TULMAÇ, Murat vd. "Fondaparinux used for severe heparin induced thrombocytopenia with subacute instent thrombosis". Yeni Tıp Dergisi 25/3 (2008), 189-191.